{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:38:12Z","timestamp":1762522692792,"version":"3.41.2"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Increased expression of interferon (IFN)-stimulated genes (ISGs) in peripheral blood, has been previously reported in viral infections, as well as in autoimmune disorders, in association with reduced leukocyte and platelet counts. Though cytopenias are common in patients with COVID-19 disease and predict severe outcomes, the underlying mechanisms have not been fully elucidated. In the current study, we aimed to determine the prevalence of hematological abnormalities in the setting of active COVID-19 infection and to explore whether they associate with disease outcomes and activation of type I IFN pathway. One-hundred-twenty-three consecutive SARS-CoV2 infected patients were included in the study. Clinical and laboratory parameters were recorded for all study participants. In 114 patients, total RNA was extracted from whole peripheral blood and subjected to real time PCR. The relative expression of three interferon stimulated genes (ISGs; IFIT1, MX-1, and IFI44) was determined and a type I IFN score reflecting peripheral type I IFN activity was calculated. The rates of anemia, leukopenia, and thrombocytopenia were 28.5, 14.6, and 24.4%, respectively. Among leukocytopenias, eosinopenia, and lymphopenia were the most prominent abnormalities being found in 56.9 and 43.1%, respectively. Of interest, patients with either eosinopenia and\/or thrombocytopenia but no other hematological abnormalities displayed significantly increased peripheral type I IFN scores compared to their counterparts with normal\/high eosinophil and platelet counts. While eosinopenia along with lymphopenia were found to be associated with increased risk for intubation and severe\/critical disease, such an association was not detected between other hematological abnormalities or increased type I IFN scores. In conclusion, hematological abnormalities are commonly detected among patients with COVID-19 infection in association with severe disease outcomes and activation of the type I IFN pathway.<\/jats:p>","DOI":"10.3389\/fmed.2022.850472","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T07:17:47Z","timestamp":1647501467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes"],"prefix":"10.3389","volume":"9","author":[{"given":"Vasiliki E.","family":"Georgakopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Lembessis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampos","family":"Skarlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Gkoufa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos V.","family":"Sipsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clio P.","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/1744666X.2021.1939686","article-title":"Type I interferon detection in autoimmune diseases: challenges and clinical applications","volume":"17","author":"Papadopoulos","year":"2021","journal-title":"Expert Rev Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10875-021-01060-0","article-title":"Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma","volume":"41","author":"Vazquez","year":"2021","journal-title":"J Clin Immunol."},{"key":"B6","first-page":"570","article-title":"Hematological consequences of pandemic influenza H1N1 infection: a single center experience","volume":"52","author":"Unal","year":"2010","journal-title":"Turk J Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3928\/0090-4481-19961001-06","article-title":"Hematologic manifestations of viral infections","volume":"25","author":"Friedman","year":"1996","journal-title":"Pediatr Ann."},{"key":"B8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ajh.25829","article-title":"Hematological findings and complications of COVID-19","volume":"95","author":"Terpos","year":"2020","journal-title":"Am J Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.21873\/invivo.12303","article-title":"The impact of peripheral eosinophil counts and eosinophil to lymphocyte ratio (ELR) in the clinical course of COVID-19 patients: a retrospective study","volume":"35","author":"Georgakopoulou","year":"2021","journal-title":"In vivo."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12865-015-0092-1","article-title":"Human platelets and their capacity of binding viruses: meaning and challenges?","volume":"16","author":"Chabert","year":"2015","journal-title":"BMC Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/16078454.2019.1590961","article-title":"Etiology and clinico-hematological profile of pancytopenia: experience of a Mexican Tertiary Care Center and review of the literature","volume":"24","author":"Vargas-Carretero","year":"2019","journal-title":"Hematology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.12669\/pjms.295.3458","article-title":"The common causes leading to pancytopenia in patients presenting to tertiary care hospital","volume":"29","author":"Das Makheja","year":"2013","journal-title":"Pak J Med Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ijlh.13425","article-title":"Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection","volume":"43","author":"Soni","year":"2021","journal-title":"Int J Lab Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e14047","DOI":"10.1111\/ijcp.14047","article-title":"Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia","volume":"75","author":"Cazzaniga","year":"2021","journal-title":"Int J Clin Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3201\/eid1005.030640","article-title":"Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients","volume":"10","author":"Wang","year":"2004","journal-title":"Emerg Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/bmj.326.7403.1358","article-title":"Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis","volume":"326","author":"Wong","year":"2003","journal-title":"BMJ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3892\/ijmm.14.2.311","article-title":"Hematological findings in SARS patients and possible mechanisms","volume":"14","author":"Yang","year":"2004","journal-title":"Int J Mol Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00277-020-04019-0","article-title":"Mechanism of thrombocytopenia in COVID-19 patients","volume":"99","author":"Xu","year":"2020","journal-title":"Ann Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4269\/ajtmh.20-1536","article-title":"Hematological abnormalities in COVID-19: a narrative review","volume":"104","author":"Rahman","year":"2021","journal-title":"Am J Trop Med Hyg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1003648","DOI":"10.1371\/journal.pmed.1003648","article-title":"Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: possible paths to platelet factor 4 autoimmunity","volume":"18","author":"Goldman","year":"2021","journal-title":"PLoS Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/17474086.2020.1831383","article-title":"D-dimer level in COVID-19 infection: a systematic review","volume":"13","author":"Rostami","year":"2020","journal-title":"Expert Rev Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/all.14455","article-title":"Eosinopenia is associated with greater severity in patients with coronavirus disease 2019","volume":"76","author":"Zhao","year":"2021","journal-title":"Allergy."},{"key":"B26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/ajcp\/aqaa062","article-title":"COVID-19 autopsies, Oklahoma, USA","volume":"153","author":"Barton","year":"2020","journal-title":"Am J Clin Pathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/j.1538-7836.2011.04530.x","article-title":"Expression and functionality of type I interferon receptor in the megakaryocytic lineage","volume":"9","author":"Negrotto","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s10072-015-2348-1","article-title":"Interferon-\u03b2 therapy and risk of thrombocytopenia in multiple sclerosis patients","volume":"36","author":"Koudriavtseva","year":"2015","journal-title":"Neurol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"906","DOI":"10.4049\/jimmunol.1302112","article-title":"Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus","volume":"192","author":"Palanichamy","year":"2014","journal-title":"J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.iac.2007.06.003","article-title":"Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon","volume":"27","author":"Butterfield","year":"2007","journal-title":"Immunol Allergy Clin North Am."},{"key":"B32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ni.3308","article-title":"Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells","volume":"17","author":"Duerr","year":"2016","journal-title":"Nat Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clineuro.2004.02.010","article-title":"IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines","volume":"106","author":"Sega","year":"2004","journal-title":"Clin Neurol Neurosurg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.3389\/fimmu.2018.02330","article-title":"Enhanced interferon-\u03b2 response contributes to eosinophilic chronic rhinosinusitis","volume":"9","author":"Jang","year":"2018","journal-title":"Front Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/BOR.0000000000000087","article-title":"Advances in understanding the role of type I interferons in systemic lupus erythematosus","volume":"26","author":"Crow","year":"2014","journal-title":"Curr Opin Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e000508","DOI":"10.1136\/rmdopen-2017-000508","article-title":"Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus","volume":"3","author":"Tyd\u00e9n","year":"2017","journal-title":"RMD Open."},{"key":"B37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41581-020-00357-4","article-title":"Immunity, endothelial injury and complement-induced coagulopathy in COVID-19","volume":"17","author":"Perico","year":"2021","journal-title":"Nat Rev Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"746203","DOI":"10.3389\/fimmu.2021.746203","article-title":"Blood transcriptomes of anti-SARS-CoV-2 antibody-positive healthy individuals who experienced asymptomatic versus clinical infection","volume":"12","author":"Sfikakis","year":"2021","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.immuni.2021.05.010","article-title":"Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease","volume":"54","author":"Bergamaschi","year":"2021","journal-title":"Immunity."},{"key":"B40","doi-asserted-by":"publisher","first-page":"28344","DOI":"10.1073\/pnas.2016650117","article-title":"SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling","volume":"117","author":"Miorin","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e51252","DOI":"10.15252\/embr.202051252","article-title":"SARS-CoV-2 evades immune detection in alveolar macrophages","volume":"21","author":"Dalskov","year":"2020","journal-title":"EMBO Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.it.2021.02.003","article-title":"Dual nature of type I interferons in SARS-CoV-2-induced inflammation","volume":"42","author":"King","year":"2021","journal-title":"Trends Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science."},{"key":"B45","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science."},{"key":"B46","doi-asserted-by":"publisher","first-page":"657363","DOI":"10.3389\/fimmu.2021.657363","article-title":"Circulating type I interferon levels and COVID-19 severity: a systematic review and meta-analysis","volume":"12","author":"da Silva","year":"2021","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/cells11020306","article-title":"Janus kinase signaling pathway and its role in COVID-19 inflammatory, vascular, and thrombotic manifestations","volume":"11","author":"Ravid","year":"2022","journal-title":"Cells."},{"key":"B48","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol."},{"year":"","author":"Mavragani","article-title":"Age and gender effects on type I interferon peripheral blood signature and interleukin-6 serum levels in COVID-19 convalescent individuals: a potential explanation for the variability in COVID-19 outcomes, submitted for publication","key":"B49"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3389\/fimmu.2018.03167","article-title":"Sex and pubertal differences in the type 1 interferon pathway associate with both X chromosome number and serum sex hormone concentration","volume":"9","author":"Webb","year":"2019","journal-title":"Front Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"107365","DOI":"10.1016\/j.intimp.2021.107365","article-title":"An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses","volume":"92","author":"Rahimi","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ijmm.2022.5090","article-title":"Thrombocytopenia in COVID-19 and vaccine-induced thrombotic thrombocytopenia","volume":"49","author":"Geronikolou","year":"2022","journal-title":"Int J Mol Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"349","DOI":"10.12788\/jhm.3594","article-title":"Gender differences in the presentation and outcomes of hospitalized patients with COVID-19","volume":"16","author":"Biol\u00e8","year":"2021","journal-title":"J Hosp Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","article-title":"Considering how biological sex impacts immune responses and COVID-19 outcomes","volume":"20","author":"Scully","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.850472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T07:17:52Z","timestamp":1647501472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.850472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":55,"alternative-id":["10.3389\/fmed.2022.850472"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.850472","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"850472"}}